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ABSTRACT
Neuromyelitis optica (NMO) is a severe autoimmune disease of the CNS characterized by recurrent
inflammatory events primarily involving the optic nerves and spinal cord. NMO is infrequent in children,
but early recognition is important to start adequate treatment. In this article, we review the evolving
diagnostic criteria of NMO and provide an update on the clinical and neuroimaging spectrum of the
disorder in pediatric patients, including current knowledge on immunopathogenesis and treatment
recommendations for children with NMO. Neurology® 2016;87 (Suppl 2):S59–S66
GLOSSARY
AQP4 5 aquaporin-4; AZA 5 azathioprine; CDC 5 complement-mediated cytotoxicity; IgG 5 immunoglobulin G; IPND 5
International Panel for NMO Diagnosis; IVIg 5 IV immunoglobulin; LETM 5 longitudinally extensive transverse myelitis;
MMF 5 mycophenolate mofetil; MOG 5 myelin oligodendrocyte glycoprotein; MP 5 methylprednisolone; MS 5 multiple
sclerosis; NMO5 neuromyelitis optica; NMOSD5 neuromyelitis optica spectrum disorder; ON5 optic neuritis; PE 5 plasma
exchange; RTX 5 rituximab; SLE 5 systemic lupus erythematosus; Th17 5 T-helper 17.
Although neuromyelitis optica (NMO) was previously considered a subtype of multiple sclerosis
(MS), the identification of autoimmune antibodies (NMO–immunoglobulin G [IgG]) targeted
against the aquaporin-4 (AQP4) water channel in the majority of adult patients identified NMO
as a different autoimmune disease entity.1,2
The high specificity of AQP4-IgG for NMO has allowed the identification of seropositive
patients with atypical presentations of the disease: NMO spectrum disorders (NMOSD).3
Although adults are predominantly affected, NMO/NMOSD has been increasingly recog-
nized in children, who demonstrate a spectrum of disease attacks that often involve CNS areas
beyond the optic nerves and spinal cord.4 A comprehensive update on NMO/NMOSD in the
pediatric population is provided in this article.
DEMOGRAPHICS AND EPIDEMIOLOGY The mean age at NMO presentation ranges from 32 to 45 years
in major case series. Population-based studies from Europe, Asia, and South America suggest that the
incidence of NMO ranges from 0.05 to 4/100,000/y and the prevalence from 0.52 to 4.4/100,000.5
Nevertheless, most of these studies have not stratified data by pediatric or adult age at onset.5 Pediatric
onset is relatively rare.
In a comprehensive prevalence study from Cuba, a country with a multiracial population, NMO onset prior
to the age of 20 years constituted 3.4% of all NMO cases with an overall prevalence rate of 0.12/100,000
persons.6 In this study, diagnosis was based on the Wingerchuk et al.7 1999 criteria, in which AQP4 antibody
testing was not included.
In a large study of patient samples collected at the Mayo Clinic, 5% of AQP4 antibody–positive patients
were children (,18 years), with a mean age at clinical onset of 12 years, a clear female preponderance (7:1),
mixed ethnic background, and a poorer prognosis compared with childhood MS.4
In 3 prospective studies of children with a first demyelinating syndrome, 0.6% (2/302),8 3.5% (3/86),9 and
3.7% (3/81)10 of patients were identified as having NMO over 3–6 years of follow-up. A similar study on 44
children with optic neuritis (ON) reported a final diagnosis of NMO in 7% of patients.11
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Current data suggest that pediatric-onset NMO
accounts for 3%–5% of all NMO cases, depending
on the diagnostic criteria utilized and the inclusion of
AQP4 antibody testing.
NEW DIAGNOSTIC CRITERIA The past decade has
witnessed important advances in our knowledge of
NMO, advances initiated by the discovery of the
disease-specific autoantibody NMO-IgG.1
The widely accepted diagnostic criteria were initially
proposed by investigators at Mayo Clinic in 1999,7
followed by a revision in 2006,12 both requiring ON
and transverse myelitis for NMO diagnosis. The 1999
criteria were published before the biomarker was iden-
tified. The 2006 revision was modified accordingly to
include the biomarker with at least 2 of the following
additional requirements: longitudinally extensive trans-
verse myelitis (LETM) involving 3 or more segments on
MRI; initial brain MRI nondiagnostic for MS; or
NMO-IgG seropositivity.12
The 2006 criteria have been the standard for clin-
ical and research purposes. Nevertheless, the identifi-
cation of AQP4 antibody in patients with clinical
features beyond the 2006 criteria indicated that the
phenotypic spectrum may be even broader. The term
NMOSD included clinical and radiologic syndromes
associated with AQP4 seropositivity, such as the fol-
lowing: (1) limited forms of NMO, including single
or recurrent LETM and recurrent or simultaneous
bilateral ON; (2) the Asian optic-spinal MS pheno-
type; (3) ON or myelitis associated with systemic
autoimmune diseases; and (4) ON or myelitis associ-
ated with brain lesions typical of NMO.3
In 2011, an International Panel for NMODiagnosis
(IPND) integrated by NMO experts was convened to
develop a new revision.13 According to the revised diag-
nostic criteria, a new unifying term NMOSD will be
used, which is stratified further by serologic testing
(NMOSDwith or without AQP4-IgG).13 The diagnosis
of NMOSD with positive AQP4-IgG requires one clin-
ical event involving at least one of the typical anatomic
regions (table).13 More stringent criteria with additional
MRI features are required for the diagnosis of NMOSD
without AQP4-IgG or when serologic testing is unavail-
able (table).13 The IPND achieved consensus on pediat-
ric patients and considered that revised diagnostic criteria
are appropriate, with minor modifications, in children.13
The major caveat is the lower specificity of LETM for
NMOSD diagnosis in this age group. LETM may be
observed in children with MS14 as well as in children
with ADEM15 and AQP4-IgG is rarely detected in chil-
dren with monophasic LETM.16 Thus, further valida-
tion of the IPND criteria in children is required.
CLINICAL PRESENTATION AND OUTCOME In
major pediatric case series of NMO and NMOSD,
a first clinical event of ON occurred in 50%–75%
of patients and transverse myelitis in 30%–50%,
either alone or in combination.16–18 A more diffuse
involvement of the CNS, including an ADEM-like
phenotype, can be observed in approximately 10% of
pediatric cases, resulting in a challenging diagnostic
situation. Pediatric-onset NMO has been described
following infections (influenza or herpes virus) and in
some patients following bone marrow transplantation.
NMOSD has also been observed in association with
another autoimmune disease.
Symptoms of brainstem involvement such as pro-
longed vomiting unresponsive to antiemetics, with or
without hiccups, and cranial nerve dysfunction, are
frequently described.19 Diencephalic impairment is
rare and includes endocrinopathies and disorders of
water balance.4 Further relapses occur in more than
90% of patients with NMOSD and the reported
monophasic course was often a consequence of lim-
ited longitudinal observation.16–18
In a French study of patients with NMOSD with
a long-term follow-up, pediatric onset was associated
with more frequent and disabling ON, more diffuse
brain lesions on MRI, and lower mortality than in pa-
tients with adult onset.18 Outcome was also marked
by the occurrence of cerebral symptoms in 45%–55%
of patients, including cognitive decline, seizures,
aphasia, narcolepsy, and ataxia.4
NEUROIMAGING FINDINGS IN CHILDREN According
to previous reports, brain lesions appear more often in
pediatric-onset anti-AQP4 antibody-positive NMOSD
compared to adult-onset cases.4,17–20 These brain lesions
are usually large (.2 cm)18 and tend to localize to areas of
high AQP4 expression such as periventricular regions of
the III (diencephalic) and IV ventricles (brainstem),
supratentorial and infratentorial white matter, midbrain,
and cerebellum.4 Gadolinium enhancement can be seen
in around one-third of patients with brain lesions,4,17
often with a cloud-like pattern of enhancement.
Diencephalic (figure 1A), hypothalamic, and area
postrema (figure 1B) lesions may be unique to AQP4
antibody-positive cases, having an important role in
differentiating NMOSD from other inflammatory
disorders of the CNS particularly in children. Similar
to ADEM, acute brain lesions tend to resolve on
repeated MRIs after treatment.17
Involvement of optic nerves is usually identified
as high-signal longitudinal lesions extending over
.1/2 optic nerve length in T2-weighted or short-
T1 inversion recovery images, frequently extending
posteriorly into the optic chiasm (figure 2). Acute
ON is usually identified by gadolinium enhance-
ment, while optic nerve atrophy can be seen in
a chronic phase of severely damaged optic nerves.
Gadolinium enhancement involving intraorbital fat
S60 Neurology 87 (Suppl 2) August 30, 2016
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
tissue can be observed in children with ON related
to NMOSD (figure 3).
Although acute transverse myelitis is not observed
as frequently as ON at presentation, it occurs in most
children at relapses.4 Spinal cord lesions on MRI are
usually characterized by extensive centrally located
high-signal lesion on T2-weighted images spanning
at least 3 segments (figure 4). The spinal cord appears
swollen and may show an irregular patchy gadolinium
enhancement. Cervical longitudinal myelitis may
spread upward into the brainstem. An atypical spinal
MRI pattern with a multicystic cord lesion recently has
been reported in a young girl with seropositive
NMOSD.21
CURRENT IMMUNOPATHOGENESIS KNOWLEDGE
This is an active area of research that involves nearly
every component of the human immune system. Based
on in vitro tissue and cell culture systems, animal models,
and human trials, the emerging hypothetical understand-
ing of the mechanisms that trigger an inflammatory
Table Revised NMOSD diagnostic criteriaa
A. NMOSD with AQP4-IgG 1. $1 Core clinical characteristic
2. Positive AQP4-IgG testing using best available method
3. Exclusion of alternative diagnoses
B. NMOSD without AQP4-IgG or with
unknown AQP4-IgG status
1. $2 Core clinical characteristics occurring as a result
of $1 clinical attacks and meeting all of the following:
a. At least 1 clinical characteristic: Must be optic neuritis,
LETM, or area postrema syndrome
b. Dissemination in space ($2 different core clinical characteristics)
c. Fulfillment of additional MRI requirements
2. Negative tests for AQP4-IgG using best available
or testing unavailable
3. Exclusion of alternative diagnoses
C. Core clinical characteristics 1. Optic neuritis
2. Acute myelitis
3. Area postrema syndrome
4. Acute brain stem syndrome
5. Symptomatic narcolepsy or acute diencephalic syndrome
with typical diencephalic MRI lesions
6. Symptomatic cerebral syndrome with typical brain lesions
D. Additional MRI requirements
1. Acute optic neuritis a. Brain MRI normal or showing nonspecific white
matter lesions and
b. Optic nerve MRI with T2-hyperintense or T1-weighted
gadolinium-enhancing lesion extending over .1/2 optic
nerve length or involving optic chiasm
2. Acute myelitis Requires intramedullary MRI lesion extending over $3 contiguous
segments (LETM) or $3 contiguous segments of spinal cord atrophy
in patients with history compatible with acute myelitis
3. Area postrema syndrome Requires associated dorsal medulla/area postrema lesions
4. Acute brainstem syndrome Requires associated periependymal brainstem lesions
Abbreviations: AQP4 5 aquaporin-4; IgG 5 immunoglobulin G; LETM 5 longitudinally extensive transverse myelitis;
NMOSD 5 neuromyelitis optica spectrum disorder.
aModified from Wingerchuk et al.13
Figure 1 Diencephalic and area postrema lesions in pediatric neuromyelitis
optica spectrum disorder
Twelve-year-old girl presenting with intractable vomiting, further developing optic neuritis
and longitudinally extensive transverse myelitis (positive aquaporin-4 immunoglobulin G).
(A) Axial fluid-attenuated inversion recovery imaging shows typical diencephalic signal
changes (black arrows). (B) Sagittal T2-weighted brain MRI with hyperintense lesion in brain-
stem involving dorsal medulla (area postrema) (white arrow).
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attack against the optic nerves and spinal cord in NMO
is that it begins in the peripheral immune system.
The earliest steps in the pathogenesis of NMO may
involve molecular mimicry between human AQP4
and nonhuman sequences that resemble AQP4. The
important role of T cells in this early process is high-
lighted by a recent animal model that suggests T cells
primed specifically against a region within the second
extracellular loop of AQP4 are enough to cause an
NMO-like disease in mice. Although AQP4 is expressed
on many solid organs in the body, AQP4-reactive T cells
in mice polarized to a T-helper 17 (Th17) phenotype
specifically attack only the CNS, sparing other AQP4-
expressing organs.22 In humans, this adaptive immune
process may depend on the antigen presentation capacity
of B cells; depletion of B cells from the blood with anti-
CD20 monoclonal antibody therapies is remarkably
effective at preventing relapses in NMO.23
Once the T and B cells conspire to strike the
optic nerves or spinal cord, the rest of the immune
system is recruited to help carry out the attack. Astro-
cyte damage occurs early in the process due to antibody
binding to AQP4 channels on astrocytic end-feet sur-
rounding blood vessels. Antibody binding triggers dam-
age through both complement and cell-mediated
mechanisms beginning with complement C1q binding
and activation of the classical complement cascade.
Upstream complement components C3a and C5a are
potent stimuli for recruitment of granulocytes includ-
ing neutrophils and eosinophils that attack the astrocyte
by AQP4-specific antibody-dependent cell-mediated
cytotoxicity. Downstream complement components
form the membrane attack complex and exacerbate
the damage to astrocytes through complement-
mediated cytotoxicity (CDC). Demyelination,
oligodendrocyte cell death, microglial activation, and
axonal injury are thought to be secondary consequences
of the primary attack against astrocytes. Whether and
how the purported disease pathogenesis described
above differs in children with NMO compared to
adults remains to be elucidated.
Figure 4 Spinal cord MRI pattern in pediatric
neuromyelitis optica spectrum
disorder
Aquaporin-4 antibody–positive 13-year-old girl with an acute
severe myelopathy. Sagittal T2-weighted spinal cord MRI
shows a longitudinally extensive lesion extending over more
than 3 vertebral segments involving the central spinal cord.
Figure 2 Optic chiasm MRI pattern in pediatric
neuromyelitis optica spectrum
disorder (NMOSD)
Thirteen-year-old girl presenting with bilateral visual loss
due to optic neuritis. Axial fluid-attenuated inversion recov-
ery brain imaging showed optic chiasm involvement (white
arrow). Aquaporin-4 immunoglobulin G seropositivity con-
firmed NMOSD diagnosis.
Figure 3 Optic neuritis MRI pattern in pediatric
neuromyelitis optica spectrum
disorder
Aquaporin-4 antibody–positive 15-year-old girl with left
optic neuritis. Coronal T1-weighted brain MRI depicts gado-
linium enhancement in the intraorbital fat tissue surround-
ing the optic nerve (white arrow).
S62 Neurology 87 (Suppl 2) August 30, 2016
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
AQUAPORIN-4-IGG SEROLOGY In 2004, Lennon
et al.1 described a specific pattern of patient IgG anti-
body reactivity in a tissue-based indirect
immunofluorescence assay with high specificity (but
limited sensitivity, 48%) for the relapsing form of
NMO, known as NMO-IgG (AQP4-IgG).2
Subsequent generations of antigen-specific AQP4-
IgG assay development have yielded progressive perfor-
mance improvement. The isoform of AQP4 used as
antigen (either the full-length M1 or shorter M23 iso-
form) may affect assay performance characteristics.24
ELISA usingM1-AQP4 as antigen demonstrated a sen-
sitivity of approximately 60%.24,25 Although a specificity
of 99%–100% has been reported for that assay, sus-
pected false-positive results have been encountered in
clinical laboratory practice.24 Several groups have re-
ported improved sensitivity (75%–83%) and specificity
(approaching 100%) utilizing cell-based AQP4-IgG
assays.25 In particular, flow cytometry has demonstrated
promise as a high-throughput method suitable for use
in large-scale clinical laboratories.
Different studies in children with NMOSD have
reported a wide range of AQP4-IgG seropositivity
from 17% to 80%.16–18,26 Similar to adults, NMO-
IgG seropositivity in children is usually associated
with a relapsing course.16 Nevertheless, 10%–40%
of patients diagnosed with NMOSD remain seroneg-
ative for AQP4 antibodies. Some or all of these
AQP4-seronegative patients may be affected by an
alternative autoimmune or inflammatory disease
mechanism.
MYELIN OLIGODENDROCYTE GLYCOPROTEIN
(MOG) ANTIBODIES IN CHILDREN MOG antibod-
ies have been described in a variety of pediatric demy-
elinating disease phenotypes including recurrent ON,
pediatric MS, ADEM, and monophasic or recurrent
ON following an ADEM onset (ADEM-ON).27,28
MOG antibodies, which are predominantly from the
IgG1 subtype and directed against the MOG protein
expressed at the outmost surface of the myelin sheath,
have been demonstrated to be capable of inducing
CDC in vitro.
Anti-MOG seropositivity has also been found in
a subgroup of adults29,30 and children31 with AQP4
antibody seronegative NMOSD. The relationship
appears to be reciprocal, with no patients reported
to have both MOG and AQP4 antibodies. In cohorts
of adult patients with NMOSD, reported frequencies
of MOG antibodies range from 7% to 20%. In adults
and children, the female to male ratio is nearly equal,
and adults with MOG antibodies are younger than
those without. Clinical evaluation suggests that pa-
tients with NMOSD with positive anti-MOG
response and negative anti-AQP4 serotype tend to
have fewer severe attacks, bilateral ON, and more
caudal myelitis, and recover better than patients with
AQP4 antibodies and those who were seronegative
for both antibodies.29,30
Disseminated brain lesions resembling those
described in ADEM and NMOSD may be identified
in children with MOG antibodies, although these le-
sions rarely involve periependymal areas and are pref-
erentially seen involving basal ganglia. These brain
MRI lesions demonstrate resolution in follow-up
imaging, without new T2, fluid-attenuated inversion
recovery, or gadolinium-enhancing lesions.
Overall, it appears that MOG antibodies are pres-
ent in a variety of pediatric inflammatory disorders,
some of them with a phenotype consistent with
NMOSD. It may be important to recognize this par-
ticular subset of patients with NMOSD who may
have a distinct underlying disease mechanism.
COEXISTING AUTOIMMUNE DISEASES AND
AUTOANTIBODIES The coexistence of other auto-
immune diseases and autoantibody accompaniments
further distinguish pediatric NMOSD from MS.
Commonly encountered autoimmune diseases include
organ-specific disorders (e.g., thyroid disease, type 1
diabetes, celiac disease) and non-organ-specific
disorders (systemic lupus erythematosus [SLE],
Sjögren syndrome).4 Autoantibody biomarkers of
these disorders are also frequently detected in
patients with NMOSD, sometimes without the
associated clinical disorder. Antinuclear antibodies are
the most frequently found non-organ-specific
autoantibodies (64%).4 Of note, AQP4-IgG is not
detected in patients with Sjögren syndrome or
SLE without CNS involvement. Organ-specific
autoantibodies routinely detected in patients with
NMOSD include thyroid peroxidase and
thyroglobulin antibodies (13%), while phospholipid
antibodies and celiac disease–related antibodies have
also been described.
Coexisting neural autoantibodies are commonly
detected in AQP4-IgG seropositive patients with
NMOSD and rarely in patients with MS. A report
including children with NMOSD described that
muscle acetylcholine receptor antibody was the most
common coexisting neural antibody detected (11%),
though just 2% had coexisting myasthenia gravis.32
Other neural autoantibodies detectable in pediatric
NMOSD include those targeting voltage-gated cal-
cium channel and potassium channel complexes,
the 65 kDa isoform of glutamic acid decarboxylase,4
as well as the NMDA receptor antibody.
TREATMENT STRATEGIES: ACUTE EVENTS AND
RELAPSE PREVENTION Treatment of NMOSD in-
cludes the management of acute attacks, prevention
of clinical exacerbations, monitoring of treatment-
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associated adverse events, and decisions regarding
switching therapy due to lack of tolerability or
treatment failure.23,33 Currently, there are no
controlled clinical trials performed in patients with
NMOSD, and treatment decisions are largely
guided by case series and expert opinions.23,33 A
consensus article on the treatment of NMOSD23
and a treatment update focused on pediatric
patients34 have been published recently.
Treatment of acute events. In an acute event, whether
the initial or an exacerbation of NMOSD, manage-
ment is focused on minimizing irreversible damage
to the CNS and restoring neurologic function.
IV methylprednisolone (MP). The recommended daily
dose of IV MP is 30 mg/kg/d to a maximum of 1,000
mg daily, for 5 consecutive days.
Plasma exchange (PE). Retrospective studies and case
series including children with NMOSD have re-
ported marked improvement in visual and motor
function following PE (5–7 cycles).23,33
IV immunoglobulin (IVIg) therapy. A small study has
reported successful relapse improvement in half of pa-
tients with NMOSD using IVIg after lack of response
to steroids.33 Interestingly, the effect of human IgG in
reducing lesion severity in a rat model has been re-
ported recently, providing mechanistic data to
encourage further clinical assessment.35
Preventive therapy. Azathioprine (AZA). Two retrospec-
tive studies including children with NMOSD36,37 re-
ported marked reductions in relapse rates (89%), with
60% of patients remaining relapse-free at 18 months,
using 2–3 mg/kg/d of AZA. Nevertheless, high rates
of discontinuation (46%) over time were also
reported.37
Rituximab (RTX). The recommended dose in chil-
dren is 375 mg/m2 weekly for 4 weeks, with addi-
tional IV infusions depending on the CD191 B-cell
count to maintain immunosuppression.23,34 Efficacy
in reducing relapse frequency has been reported in
children and adults with NMOSD treated with
RTX, with stabilization or improvement of
disability.23,38
Mycophenolate mofetil (MMF). The use of MMF was
well-tolerated and induced reduction of relapse
frequency with improvement of disability in 2 retro-
spective studies including children (median dose
2,000 mg/d).39
Methotrexate.A sustained remission (36months) was
reported in a single child treated with methotrexate.4
Cyclophosphamide. Most of the few children treated
with monthly IV cyclophosphamide pulse (1,000
mg/m2) for 6 months needed to be switched to other
therapies due to lack of efficacy.4,16,18
Mitoxantrone hydrochloride. The use of mitoxantrone
in pediatric NMOSD is limited to a single patient18
who was finally switched to other treatments (AZA
and MMF).
Combination therapies. Oral steroids combined
with AZA is the most frequently used combination
therapy.36 Cyclosporine A with low-dose oral steroids
also has been reported as effective in adult patients
with NMOSD.40
Treatments not recommended for patients with
NMOSD. Interferon-b, natalizumab, and fingolimod
can precipitate dramatic flare-up of NMOSD.23,33
Alemtuzumab has been reported as ineffective in
adult patients with NMOSD. The use of
mitoxantrone and cyclophosphamide also should
be avoided in children considering their potential
severe side effects.
New therapeutic agents. Considering that current
NMOSD treatment is only partially effective, new
agents are being evaluated in trials, including the
following:
1. Eculizumab (anti-C5 monoclonal antibody)
2. Tocilizumab (anti-IL-6R monoclonal antibody
targeting T- and B-cell activation, Th17 differen-
tiation, and plasmablast survival)
3. Aquaporumab (competitive, nonpathogenic anti-
AQP4-specific antibody)
4. Neutrophil elastase inhibitors
5. Antihistamines with eosinophil-stabilizing actions
6. Enzymatic AQP4-IgG deglycosylation or cleavage
Treatment recommendations. Considering the current
evidence, the following treatment recommendations
for pediatric NMOSD may be suggested23,34:
1. Initial therapies: AZA (with oral steroid), RTX, or
MMF
2. Patient monitoring with blood and liver function
tests
3. In case of adverse events or poor response: Treat-
ment may be switched from AZA to RTX or
MMF
4. In case of continuing poor response: A combina-
tion of immunosuppression and chronic intermit-
tent PE may be considered
5. IVIg may be used as initial therapy when immu-
nosuppression is contraindicated
6. In case of continuing disease progression: Newer
agents may be considered
FUTURE DIRECTIONS Progress in terms of improved
diagnostic and treatment approach seen in adults and
a better understanding of NMOSD pathophysiology
may be extrapolated to children. Treatment options
for children with NMOSD are available, and will con-
tinue to expand. Nevertheless, more studies in the
pediatric population with NMOSD are necessary,
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including alternative pathways for AQP4-seronegative
children, and more data on long-term safety and
treatment response of the old and newer therapeutic
agents.
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